Equities research analysts predict that Acadia Pharmaceuticals (NASDAQ:ACAD) will post $46.52 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for Acadia Pharmaceuticals’ earnings, with estimates ranging from $45.98 million to $47.05 million. Acadia Pharmaceuticals posted sales of $15.29 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 204.3%. The business is expected to issue its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Acadia Pharmaceuticals will report full-year sales of $46.52 million for the current financial year, with estimates ranging from $257.13 million to $262.77 million. For the next fiscal year, analysts expect that the business will post sales of $383.10 million per share, with estimates ranging from $329.75 million to $436.45 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Acadia Pharmaceuticals.
Acadia Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.55) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.03. Acadia Pharmaceuticals had a negative net margin of 231.71% and a negative return on equity of 73.02%. The firm had revenue of $43.56 million for the quarter, compared to analyst estimates of $45.30 million.
Several research analysts have issued reports on ACAD shares. Zacks Investment Research raised shares of Acadia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a research report on Tuesday, January 9th. BidaskClub raised shares of Acadia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, February 17th. Finally, ValuEngine downgraded shares of Acadia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, March 23rd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and ten have given a buy rating to the stock. Acadia Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $49.50.
Acadia Pharmaceuticals stock traded down $0.60 during midday trading on Monday, hitting $21.53. 1,131,111 shares of the company’s stock were exchanged, compared to its average volume of 1,623,822. Acadia Pharmaceuticals has a 12-month low of $20.62 and a 12-month high of $41.20. The company has a market capitalization of $2,759.65, a P/E ratio of -9.12 and a beta of 3.43.
In other news, EVP Glenn Baity sold 36,558 shares of Acadia Pharmaceuticals stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $32.39, for a total value of $1,184,113.62. Following the sale, the executive vice president now owns 83,734 shares of the company’s stock, valued at $2,712,144.26. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Daniel B. Soland bought 7,000 shares of the stock in a transaction dated Thursday, March 1st. The stock was purchased at an average cost of $23.91 per share, for a total transaction of $167,370.00. Following the acquisition, the director now owns 2,000 shares of the company’s stock, valued at $47,820. The disclosure for this purchase can be found here. 22.25% of the stock is owned by insiders.
Several large investors have recently modified their holdings of ACAD. Earnest Partners LLC purchased a new stake in shares of Acadia Pharmaceuticals in the fourth quarter valued at about $133,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Acadia Pharmaceuticals in the fourth quarter valued at about $200,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Acadia Pharmaceuticals by 43.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,670 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 1,710 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of Acadia Pharmaceuticals in the fourth quarter valued at about $219,000. Finally, Chicago Equity Partners LLC purchased a new stake in shares of Acadia Pharmaceuticals in the fourth quarter valued at about $237,000. 96.24% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/46-52-million-in-sales-expected-for-acadia-pharmaceuticals-acad-this-quarter.html.
About Acadia Pharmaceuticals
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Get a free copy of the Zacks research report on Acadia Pharmaceuticals (ACAD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acadia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acadia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.